European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of fatty liver disease?
| Autor: | Manuel Romero-Gómez, Patrizia Carrieri, Mattias Ekstedt, Shira Zelber-Sagi, Katja Novak, Vlad Ratziu, Quentin M. Anstee, Frank Tacke, Adam Palayew, Jeffrey V. Lazarus, Helena Cortez-Pinto, Giulio Marchesini |
|---|---|
| Přispěvatelé: | Instituto de Salud Global - Institute For Global Health [Barcelona] (ISGlobal), University of Barcelona, McGill University = Université McGill [Montréal, Canada], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Linköping University (LIU), Alma Mater Studiorum University of Bologna (UNIBO), Istituto di ricovero e cura a carattere scientifico Azienda Ospedaliera Universitaria 'San Martino' (IRCCS AOU San Martino), University Medical Centre Ljubljana [Ljubljana, Slovenia] (UMCL), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Liver Unit, Clínica Universitaria, CIBER-EHD, Hospital Universitario Virgen del Rocío [Sevilla], Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Haifa [Haifa], Universidade de Lisboa (ULISBOA), Newcastle University [Newcastle], Lazarus J.V., Palayew A., Carrieri P., Ekstedt M., Marchesini G., Novak K., Ratziu V., Romero-Gomez M., Tacke F., Zelber-Sagi S., Cortez-Pinto H., Anstee Q.M., EASL International Liver Foundation, Gilead Sciences, Allergan Foundation, Bristol-Myers Squibb, Pfizer, Resoundant, Intercept Pharmaceuticals, Genfit, Ministerio de Ciencia, Innovación y Universidades (España), Instituto de Salud Carlos III, European Commission, Generalitat de Catalunya, NIHR Biomedical Research Centre (UK), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Universidade de Lisboa = University of Lisbon (ULISBOA), Repositório da Universidade de Lisboa, Gestionnaire, Hal Sorbonne Université |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
ESPEN
type 2 diabetes mellitus EASL European Association for the Study of the Liver [SDV]Life Sciences [q-bio] Disease Multiple joint correspondence analysi WHO 0302 clinical medicine Non-alcoholic fatty liver disease Liver health Multiple joint correspondence analysis Policy preparedness Health policy Metabolic-associated fatty liver disease Non-alcoholic steatohepatitis Europe Multidisciplinary approach EASD European Association for the Study of Diabetes European Association for the Study of Diabetes Epidemiology Immunology and Allergy Medicine European Association for the Study of Obesity European Society of Clinical Nutrition and Metabolism EEA EASO European Association for the Study of Obesity media_common Gastroenterology NASH food and beverages ESPEN European Society of Clinical Nutrition and Metabolism 3. Good health [SDV] Life Sciences [q-bio] 030220 oncology & carcinogenesis Preparedness 030211 gastroenterology & hepatology Research Article European Association for the Study of the Liver EEA European Economic Area medicine.medical_specialty NAFLD non-alcoholic fatty liver disease EASD NASH non-alcoholic steatohepatitis multiple correspondence analysis T2DM Gastroenterology and Hepatology EASL World Health Organization digestive system WHO World Health Organization European Economic Area 03 medical and health sciences Environmental health EU European Union NAFLD Gastroenterologi Internal Medicine media_common.cataloged_instance European Union lcsh:RC799-869 European union MCA multiple correspondence analysis Hepatology business.industry Public health MCA nutritional and metabolic diseases non-alcoholic fatty liver disease T2DM type 2 diabetes mellitus medicine.disease Obesity digestive system diseases EASO lcsh:Diseases of the digestive system. Gastroenterology business EU Non-alcoholic steatohepatiti |
| Zdroj: | JHEP Reports Innovation in Hepatology JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (2), pp.100234. ⟨10.1016/j.jhepr.2021.100234⟩ Digital.CSIC. Repositorio Institucional del CSIC instname JHEP Reports JHEP Reports, Vol 3, Iss 2, Pp 100234-(2021) |
| ISSN: | 2589-5559 |
| DOI: | 10.1016/j.jhepr.2021.100234⟩ |
| Popis: | [Background & Aims] Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent emerging condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to ensure that health systems can deliver effective care. We present a NAFLD Preparedness Index for Europe. [Methods] In June 2019, data were extracted by expert groups from 29 countries to complete a 41-item questionnaire about NAFLD. Questions were classified into 4 categories: policies/civil society (9 questions), guidelines (16 questions), epidemiology (4 questions), and care management (12 questions). Based on the responses, national preparedness for each indicator was classified into low, middle, or high-levels. We then applied a multiple correspondence analysis to obtain a standardised preparedness score for each country ranging from 0 to 100. [Results] The analysis estimated a summary factor that explained 71.3% of the variation in the dataset. No countries were found to have yet attained a high-level of preparedness. Currently, the UK (75.5) scored best, although falling within the mid-level preparedness band, followed by Spain (56.2), and Denmark (43.4), whereas Luxembourg and Ireland were the lowest scoring countries with a score of 4.9. Only Spain scored highly in the epidemiology indicator category, whereas the UK was the only country that scored highly for care management. [Conclusions] The NAFLD Preparedness Index indicates substantial variation between countries’ readiness to address NAFLD. Notably, even those countries that score relatively highly exhibit deficiencies in key domains, suggesting that structural changes are needed to optimise NAFLD management and ensure effective public health approaches are in place. [Lay summary] Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to allow for effective public health measures aimed at preventing disease while also ensuring that health systems can deliver effective care to affected populations. This study defined preparedness as having adequate policies and civil society engagement, guidelines, epidemiology, and care management. NAFLD preparedness was found to be deficient in all 29 countries studied, with great variation among the countries and the 4 categories studied. The original data collection was funded by the EASL International Liver Foundation with support from Gilead Sciences Europe Ltd., Allergan Pharmaceutical International Ltd., Bristol-Myers-Squibb Company, Pfizer Inc., and Resoundant Inc. The statistical analysis was funded by the EASL International Liver Foundation with support from Bristol-Myers-Squibb Company, Intercept, and Genfit. JVL is supported by a Spanish Ministry of Science, Innovation and Universities Miguel Servet grant (Instituto de Salud Carlos III/ESF, European Union [CP18/00074]) and further acknowledges institutional support from the Spanish Ministry of Science, Innovation and Universities through the ‘Centro de Excelencia Severo Ochoa 2019–2023’ Programme (CEX2018-000806-S), and support from the Government of Catalonia through the CERCA Programme. QMA and VR are members of the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413. QMA, VR, HCP, ME, and MRG are members of the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium funded by the IMI2 Program of the European Union under Grant Agreement 777377. QMA is a Newcastle NIHR Biomedical Research Centre investigator. AP, PC, GM, KN, FT, and SZS have no financial support statements to disclose. With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2018-000806-S). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|